;
Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Roche to acquire IQuum

    Roche (SIX:ROG; OTCQX:RHHBY) will acquire molecular diagnostics company IQuum Inc. (Marlborough, Mass.) for $275 million in cash up front and up to $175 million in milestones. Roche will gain IQuum's Liat Analyzer …

    Published on 4/7/2014
  • COMPANY NEWS: Sun to acquire Ranbaxy

    Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) will acquire fellow Indian generics company Ranbaxy Laboratories Ltd. (BSE:500359; NSE:RANBAXY) in an all-stock deal that the companies said values Ranbaxy …

    Published on 4/7/2014
  • COMPANY NEWS: Zogenix challenging Massachusetts' Zohydro ban

    Zogenix Inc. (NASDAQ:ZGNX) filed suit against Massachusetts Gov. Deval Patrick and Cheryl Bartlett, commissioner of the Massachusetts Department of Public Health, in the U.S. District Court for the District of …

    Published on 4/7/2014
  • COMPANY NEWS: AbbVie drops suits against EMA

    AbbVie Inc. (NYSE:ABBV) dropped two lawsuits against EMA challenging the agency's decision to grant access to raw patient-level data for the company's autoimmune drug Humira adalimumab. AbbVie filed suit last year in …

    Published on 4/4/2014
  • COMPANY NEWS: Mylan sues Celgene for blocking access to Revlimid, Thalomid

    Generics company Mylan Inc. (NASDAQ:MYL) filed suit in the U.S. District Court for the District of New Jersey alleging that Celgene Corp. (NASDAQ:CELG) is violating antitrust laws by preventing Mylan from obtaining …

    Published on 4/4/2014
  • COMPANY NEWS: NICE backs Lemtrada for RRMS

    The U.K.'s NICE issued a final appraisal determination recommending Lemtrada alemtuzumab from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat relapsing-remitting multiple sclerosis (RRMS). In December…

    Published on 4/4/2014
  • COMPANY NEWS: Roche names Berger oncology/hematology development head

    Roche (SIX:ROG; OTCQX:RHHBY) named Dietmar Berger as SVP and global head of clinical development for oncology and hematology. Berger was VP of global clinical development for the pharma's HER2-targeted breast cancer …

    Published on 4/4/2014
  • COMPANY NEWS: Amgen regains denosumab rights from GSK

    Amgen Inc. (NASDAQ:AMGN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) mutually agreed to end part of a 2009 deal under which GSK had rights to co-commercialize Amgen's Prolia denosumab for postmenopausal osteoporosis in …

    Published on 4/3/2014
  • COMPANY NEWS: Astellas submits EU application to expand Xtandi's label

    Medivation Inc. (NASDAQ:MDVN) and partner Astellas Pharma Inc. (Tokyo:4503) said Astellas submitted an MAA to EMA to expand the label of Xtandi enzalutamide to include treatment of metastatic castration-resistant …

    Published on 4/3/2014
  • COMPANY NEWS: FDA approves naloxone autoinjector for opioid overdose

    FDA approved Evzio naloxone from Kaleo Inc. (Richmond, Va.) for the emergency treatment of suspected or known opioid overdose. The product is a hand-held autoinjector that provides verbal instructions to rapidly deliver…

    Published on 4/3/2014
  • COMPANY NEWS: FDA to review Fibrocaps

    The Medicines Co. (NASDAQ:MDCO) said FDA accepted for review a BLA for Fibrocaps to aid in hemostasis during surgery when control of mild or moderate bleeding by conventional means is ineffective or impractical. The …

    Published on 4/3/2014
  • COMPANY NEWS: G-BA rejects GSK's Tafinlar

    Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Tafinlar dabrafenib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has "no additional benefit" vs. Zelboraf vemurafenib from Roche (SIX:ROG;…

    Published on 4/3/2014
  • COMPANY NEWS: Sekhri joins Sanofi as SVP of integrated care

    Sanofi (Euronext:SAN; NYSE:SNY) hired Paul Sekhri as SVP of integrated care. He was group EVP of global business development and chief strategy officer at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

    Published on 4/3/2014
  • COMPANY NEWS: 23andMe names Hibbs chief legal, regulatory officer

    Personal genomics company 23andMe Inc. (Mountain View, Calif.) hired Kathy Hibbs as chief legal and regulatory officer. Hibbs was SVP and general counsel at cancer diagnostic company Genomic Health Inc. (NASDAQ:GHDX), …

    Published on 4/2/2014
  • COMPANY NEWS: Celltrion files suit to clear U.S. path for biosimilar Remicade

    Celltrion Inc. (KOSDAQ:068270) filed suit in the U.S. District Court for the District of Massachusetts seeking a declaratory judgment that three patents from Johnson & Johnson (NYSE:JNJ) covering the pharma's autoimmune…

    Published on 4/2/2014
  • COMPANY NEWS: EMA accepts Zerenex MAA for review

    Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said EMA accepted for review an MAA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic kidney disease…

    Published on 4/2/2014
  • COMPANY NEWS: Myriad gains after CMS ups BRCA reimbursement

    Myriad Genetics Inc. (NASDAQ:MYGN) gained $4.03 (11%) to $39.18 on Wednesday after disclosing in an SEC filing that CMS increased its reimbursement rate for genetic tests for breast cancer 1 early onset (BRCA1) and …

    Published on 4/2/2014
  • COMPANY NEWS: FDA panel backs MannKind's Afrezza

    FDA's Endocrinologic and Metabolic Drugs Advisory Committee said MannKind Corp. (NASDAQ:MNKD) showed that Afrezza is safe and effective to treat Type I and II diabetes. The panel voted 13-1, with one abstention, that …

    Published on 4/1/2014
  • COMPANY NEWS: IQWiG backs Bayer's Xofigo

    Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that Xofigo radium-223 dichloride from Bayer AG (Xetra:BAYN) has "major" additional benefit vs. best …

    Published on 4/1/2014
  • COMPANY NEWS: IQWiG backs Roche's Kadcyla for some

    Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Kadcyla ado-trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) has "major" additional benefit vs. Tyverb lapatinib plus the pharma's Xeloda …

    Published on 4/1/2014
  • COMPANY NEWS: IQWiG rebuffs Gilead's HIV drug Eviplera

    Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from Gilead Sciences Inc. (NASDAQ:GILD) has "no …

    Published on 4/1/2014
  • COMPANY NEWS: Janssen submits darunavir/cobicistat NDA

    The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for a fixed-dose combination of J&J's HIV drug darunavir and cobicistat from Gilead Sciences Inc. (NASDAQ:GILD) to …

    Published on 4/1/2014
  • COMPANY NEWS: MDCO falls on mixed Angiomax decision

    The Medicines Co. (NASDAQ:MDCO) fell $4.40 (15%) to $24.02 on Tuesday after the U.S. District Court for the District of Delaware found that two of the company's patents covering anticoagulant Angiomax bivalirudin are …

    Published on 4/1/2014
  • COMPANY NEWS: Sanofi pulls Lyxumia in Germany

    Sanofi (Euronext:SAN; NYSE:SNY) said it will no longer market Type II diabetes drug Lyxumia lixisenatide in Germany after failing to agree on a price with Germany's Statutory Health Insurance Funds Association (GKV-…

    Published on 4/1/2014
  • COMPANY NEWS: AstraZeneca, MRC in screening deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN) and the U.K.'s Medical Research Council are partnering to evaluate over 2 million AstraZeneca molecules under a five-year deal. The council will fund up to 15 screening projects per …

    Published on 3/31/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993